UNSPSC 51162633: Levodropropizine

This classification denotes an antitussive agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3O31P6T4G3, chemically known as 1,2-propanediol, 3-(4-phenylpiperazin-1-yl)-, s(-)- but more generally known as levodropropizine, which bears US NIH Compound Identifier 65859. European Medicines Agency schedules Levodropropizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12105MIG. The term LEVODROPROPIZINE is an International Non-Proprietary Name.

UNSPSC 51162633 Levodropropizine is a Commodity code representing pharmaceutical products being procured by state and local governments, though recent activity shows the code tagged to acquisitions of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals rather than levodropropizine specifically. State and local buyers under this code include county health departments and multistate cooperative purchasing alliances administering pharmaceutical procurement for distributed public-health networks. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are the issuing bodies visible in recent opportunities, both sourcing pharmaceutical products through competitive processes for health and community-support functions. The scope of work reflects public-health pharmaceutical supply — naloxone for overdose response, drug deactivation systems for safe disposal, and generic OTC medications distributed through authorized wholesale networks to state and local facilities.

Recent opportunities span Florida and Minnesota with multistate reach. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards, with evaluation weighted 75 percent on price competitiveness. Seminole County issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, bidders due July 26, 2023, with FEMA potential funding and a two-year initial term plus one-year renewal option. The code shows limited recent activity and a disconnect between the nominal commodity (levodropropizine, an antitussive) and actual recent procurements (naloxone, OTC generics, and harm-reduction systems).